Skip to main content
. 2021 Aug 15;11(4):462–470.

Table 1.

Characteristics of study population and incidence of forearm hematoma with different clinico-demographic factors

Patient characteristics Total (n=1754) Hematoma

Present (n=187) Absent (n=1567)
Age (mean ± SD, years) 56.3±10.6 56.2±11.3 56.3±10.5
Female, n (%) 312 (17.8%) 52 (27.8%) 260 (16.6%)
Body weight (mean ± SD, kg) 64.4±9.0 64.2±9.1 64.4±9.0
Hypertension, n (%) 666 (38.0%) 68 (36.4%) 598 (38.2%)
Diabetes mellitus, n (%) 622 (35.5%) 67 (35.8%) 555 (35.4%)
Smoking, n (%) 570 (32.5%) 70 (37.4%) 500 (31.9%)
Hemoglobin (mean ± SD, g/dl) 12.8±1.7 12.6±1.9 12.7±1.6
Serum Creatinine (mean ± SD, mg/dl) 1.06±0.46 1.02±0.26 1.06±0.47
GFR (mean ± SD, ml/min) 73.9±24.5 73.2+22.9 74.1±24.7
Homeostasis time, n (%)
    ≤360 min 802 (45.7%) 49 (26.2%) 753 (48.1%)
    >360 min 952 (54.3%) 138 (73.8%) 814 (51.9%)
GFR (ml/min), n (%)
    ≤60 542 (30.9%) 58 (31.0%) 484 (30.9%)
    >60 1212 (69.1%) 129 (69.0%) 1083 (69.1%)
Multiple puncture attempts, n (%)
    No 1091 (62.2%) 89 (47.6%) 1002 (63.9%)
    Yes 663 (37.8%) 98 (52.4%) 565 (36.1%)
Contrast volume (ml), n (%)
    <100 ml 388 (22.1%) 40 (21.4%) 348 (22.2%)
    ≥100 ml 1366 (77.9%) 147 (78.6%) 1219 (77.8%)
Sheath size, n (%)
    5F 378 (21.6%) 40 (21.4%) 338 (21.6%)
    6F 1367 (77.9%) 140 (74.9%) 1227 (78.3%)
    7F 9 (0.5%) 7 (3.7%) 2 (0.1%)
Antiplatelet treatment, n (%)
    Conventional 1455 (83.0%) 128 (68.4%) 1327 (84.7%)
    Intensive 299 (17.0%) 59 (31.6%) 240 (15.3%)
Heparin dose, n (%)
    5000 units 380 (21.7%) 40 (21.4%) 340 (21.7%)
    >5000 units 1374 (78.3%) 147 (78.6%) 1227 (78.3%)
Diagnostic vs. therapeutic procedure, n (%)
    Angiography 380 (21.7%) 40 (21.4%) 340 (21.7%)
    Angioplasty 1374 (78.3%) 147 (78.6%) 1227 (78.3%)
Complexity of procedure, n (%)
    Simple 1618 (92.2%) 153 (81.8%) 1465 (93.5%)
    Complex 136 (7.8%) 34 (18.2%) 102 (6.5%)

Continuous variables are reported in mean (standard deviation). GFR: Glomerular filtration rate; SD: Standard deviation. Intensive antiplatelet therapy: Use of dual antiplatelet therapy containing ticagrelor or prasugrel and/or use of Glycoprotein IIb/IIIa inhibitors.